EL-1007-01-01: A Double Blind, Randomized, Vehicle Controlled, Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients with the Mycosis Fungoides (MF) Form of Cutaneous T-Cell Lymphoma (CTCL)
A study for patients with Cutaneous T-Cell Lymphoma/Mycosis Fungoides using topical lotion Naloxone in the treatment of itching
Sponsor: Elorac, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAQ8604
U.S. Govt. ID: NCT02811783
Contact: Grace Ulerio: 212-305-8444 / gu2102@cumc.columbia.edu
Additional Study Information: You are being asked to participate in a research study because you have Cutaneous T-Cell Lymphoma/Mycosis Fungoides, and one of your symptoms is itching. This study is being done to assess the efficacy and safety of Naloxone HCL Lotion 0.5% compared to Vehicle Lotion for the treatment of itching in patients with mycosis fungoides (MF) which is a type of cancer called cutaneous T cell lymphomas (CTCL) that involves abnormal white blood cells in the blood and skin. Naloxone is a drug that is approved for use given directly into the blood stream for the treatment of narcotic overdose by blocking their effects. The Vehicle Lotion is the same lotion as the Naloxone Lotion, but it does not contain the active ingredient, Naloxone. This study will also determine if there is absorption of the drug into the blood in some subjects at some study sites.
This study is closed
Larisa Geskin, MD
Do You Qualify?
Are you at least 21 years of age? Yes No
Have you been diagnosed with Cutaneous T-Cell Lymphoma/Mycosis Fungoides ? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Grace Ulerio